Malignant gliomas are highly lethal tumors that resist conventional therapies. Tumor invasion into normal brain is a critical contributor to treatment failure. Despite the importance of tumor invasion, little of the biochemical pathways regulating invasion are recognized. Secreted protein, acidic and rich in cysteine (SPARC) - also known as osteonectin - is a protein frequently overexpressed in gliomas at sites of invasion. We have recently demonstrated in a gene expression study of older glioblastoma patients that SPARC expression contributes to poor outcome. In glioma cell lines, we and others have shown that SPARC expression induces invasion both in vitro and in vivo with increased matrix metalloproteinase (MMP) expression. Additionally, we have demonstrated that SPARC expression increases cellular survival under stress with increased Akt activation. Thus, SPARC may augment glioma invasion through multiple mechanisms. In our current studies, we will study the biochemical pathways initiated in response to SPARC and determine the impact of targeting SPARC expression.
In Specific Aim 1, we will define the contribution of Akt activation to SPARC-induced MMP expression and tumor invasion.
In Aim 2, we will examine the activating kinases upstream to Akt in the SPARC signaling cascade with a focus on non-receptor tyrosine kinases.
In Aim 3, we will define the impact of targeting SPARC expression with RNAi on invasion both in vitro and in vivo. These studies will contribute to the understanding of the regulation of glioma invasion and provide the basis of novel targeted therapies for gliomas. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS054276-01A1
Application #
7034992
Study Section
Clinical Neuroimmunology and Brain Tumors Study Section (CNBT)
Program Officer
Fountain, Jane W
Project Start
2006-02-15
Project End
2011-01-31
Budget Start
2006-02-15
Budget End
2007-01-31
Support Year
1
Fiscal Year
2006
Total Cost
$243,469
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Heddleston, J M; Wu, Q; Rivera, M et al. (2012) Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ 19:428-39
Hamerlik, Petra; Lathia, Justin D; Rasmussen, Rikke et al. (2012) Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med 209:507-20
Hjelmeland, Anita B; Rich, Jeremy N (2011) Molecular targeting of neural cancer stem cells: TTAGGG, you're it! Clin Cancer Res 17:3-5
Guryanova, Olga A; Wu, Qiulian; Cheng, Lin et al. (2011) Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 19:498-511
Mathieu, Julie; Zhang, Zhan; Zhou, Wenyu et al. (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71:4640-52
Eyler, Christine E; Wu, Qiulian; Yan, Kenneth et al. (2011) Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 146:53-66
Lathia, J D; Hitomi, M; Gallagher, J et al. (2011) Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis 2:e200
Lathia, Justin D; Venere, Monica; Rao, Mahendra S et al. (2011) Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev 7:227-37
Forrester, Michael T; Eyler, Christine E; Rich, Jeremy N (2011) Bacterial flavohemoglobin: a molecular tool to probe mammalian nitric oxide biology. Biotechniques 50:41-5
Hjelmeland, A B; Wu, Q; Heddleston, J M et al. (2011) Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 18:829-40

Showing the most recent 10 out of 39 publications